MINIPRESS Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Minipress, and what generic alternatives are available?

Minipress is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Minipress

A generic version of MINIPRESS was approved as prazosin hydrochloride by TEVA PHARMS on September 12^th, 1988.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for MINIPRESS?
What are the global sales for MINIPRESS?
What is Average Wholesale Price for MINIPRESS?

Summary for MINIPRESS

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	27
Patent Applications:	1,782
Drug Prices:	Drug price information for MINIPRESS
What excipients (inactive ingredients) are in MINIPRESS?	MINIPRESS excipients list
DailyMed Link:	MINIPRESS at DailyMed

Drug patent expirations by year for MINIPRESS

Recent Clinical Trials for MINIPRESS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1/Phase 2
University of Washington	Phase 4
Fast Grants	Phase 2

See all MINIPRESS clinical trials

US Patents and Regulatory Information for MINIPRESS

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MINIPRESS

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MINIPRESS

See the table below for patents covering MINIPRESS around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Malaysia	8100271	NOVEL CRYSTALLINE FORMS OF PRAZOSIN HYDROCHLORIDE	⤷ Sign Up
Denmark	145858		⤷ Sign Up
United Kingdom	1538713		⤷ Sign Up
New Zealand	183450	PREPARATION OF THE CRYSTALLINE -FORM OF 2-(4-(2-FOROYL)-PIPERAZIN-1-YL)-4-AMINO-6,7-DIMETHOXY-QUINAZDINE HYDROCHLORIDE	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for MINIPRESS

Recent Clinical Trials for MINIPRESS

Make Better Decisions: Try a trial or see plans & pricing